Cognizant, a leader in technology and consulting services, is teaming up with NVIDIA, a renowned AI platform provider, to revolutionize the field of drug discovery in the life sciences industry. By harnessing the power of generative AI technology through the NVIDIA BioNeMo platform, Cognizant aims to overcome the challenges faced in the development of life-saving treatments, including lengthy development cycles and high failure rates.
Drug discovery is a complex process that involves analyzing vast amounts of scientific literature and clinical data. Traditional methods often tend to be time-consuming, costly, and less effective. However, by leveraging the capabilities of generative AI, Cognizant’s team of experts can quickly process and evaluate extensive datasets, accurately predict interactions between drug compounds, and propose innovative pathways for drug development.
The collaboration between Cognizant and NVIDIA brings together Cognizant’s deep knowledge in the life sciences industry and AI domain with NVIDIA’s industry-specific generative AI models available through BioNeMo. This collaboration offers clients a comprehensive suite of model-making services, including pretrained models, cutting-edge frameworks, and APIs. These services enable clients to train and customize enterprise models using their proprietary data, with minimal manual intervention and without the need for complex coding or infrastructure maintenance.
According to Anna Elango, EVP of Cognizant’s Core Technologies & Insights, generative AI has the potential to transform the entire drug discovery process, making it faster, smarter, and more accessible to all. By collaborating with NVIDIA, Cognizant is paving the way for this transformative vision to be realized with utmost safety, responsibility, and cost-effectiveness for their life sciences clients.
Alvin DaCosta, VP of Global Consulting Partner Organization at NVIDIA, believes that generative AI will drive the next wave of enterprise productivity gains across various industries. With the use of NVIDIA BioNeMo, Cognizant will provide its life sciences clients with advanced and secure AI services that will result in improved outcomes and customized drug discovery applications.
This collaboration is part of Cognizant’s ongoing commitment to collaborating with global leaders in the life sciences industry. Through these partnerships, Cognizant aims to enhance science, improve patient outcomes, and increase business value by fostering a patient-centric approach and enabling seamless interactions with healthcare professionals. With Cognizant’s life sciences offerings already supporting millions of patients worldwide, this collaboration further solidifies their position as a trusted partner in the industry.
Looking ahead, Cognizant plans to extend its collaboration with NVIDIA to other sectors such as manufacturing and automotive engineering. By applying generative AI in these areas, Cognizant aims to boost productivity, optimize costs, and promote innovation in the market. As part of this commitment, Cognizant plans to establish an NVIDIA AI Center of Excellence, where they can innovate and leverage NVIDIA technologies, including the NVIDIA Metropolis, NVIDIA Omniverse, and NVIDIA AI Enterprise platforms, to benefit clients across industries globally.
In conclusion, the collaboration between Cognizant and NVIDIA marks a significant milestone in the field of drug discovery. By combining their expertise and cutting-edge AI technology, they aim to accelerate the development of life-saving treatments and drive transformative changes in the industry.
FAQ:
Q: What is generative AI?
A: Generative AI is a technology that uses algorithms to create new, original content based on existing data patterns.
Q: What is the NVIDIA BioNeMo platform?
A: The NVIDIA BioNeMo platform is a generative AI platform specifically designed for the life sciences industry. It provides industry-specific AI models, frameworks, and APIs to accelerate drug discovery processes and improve outcomes.
Q: How will this collaboration benefit life sciences clients?
A: The collaboration between Cognizant and NVIDIA will provide life sciences clients with advanced, secure, and reliable AI services for customized drug discovery applications. This will result in improved outcomes, increased productivity, and faster time to market for life-saving treatments.
Q: What other sectors will Cognizant and NVIDIA explore together?
A: Cognizant and NVIDIA plan to extend their collaboration to sectors such as manufacturing and automotive engineering, where the application of generative AI can drive productivity gains, cost optimization, and market innovation.
Sources:
– Cognizant: www.cognizant.com
– NVIDIA BioNeMo: [link to NVIDIA domain]
Cognizant’s collaboration with NVIDIA in the field of drug discovery has significant implications for the life sciences industry. This collaboration aims to address the challenges faced in developing life-saving treatments, such as lengthy development cycles and high failure rates.
The drug discovery process often involves analyzing vast amounts of scientific literature and clinical data, which can be time-consuming and less effective using traditional methods. The utilization of generative AI technology allows Cognizant’s experts to process and evaluate extensive datasets quickly, predict drug compound interactions accurately, and propose innovative pathways for development.
By bringing together Cognizant’s expertise in the life sciences industry and AI domain with NVIDIA’s generative AI models through the BioNeMo platform, clients can access a comprehensive suite of model-making services. These services include pretrained models, cutting-edge frameworks, and APIs, enabling clients to train and customize enterprise models using their proprietary data with minimal manual intervention.
Generative AI has the potential to transform the entire drug discovery process, making it faster, smarter, and more accessible. This collaboration between Cognizant and NVIDIA is paving the way for this transformative vision to be realized, ensuring safety, responsibility, and cost-effectiveness for their life sciences clients.
In addition to the life sciences industry, generative AI is expected to drive productivity gains across various sectors. Cognizant plans to extend its collaboration with NVIDIA to other industries such as manufacturing and automotive engineering. By applying generative AI in these areas, Cognizant aims to boost productivity, optimize costs, and promote innovation in the market.
This collaboration is part of Cognizant’s commitment to collaborating with global leaders in the life sciences industry. By fostering a patient-centric approach and enabling seamless interactions with healthcare professionals, Cognizant aims to enhance science, improve patient outcomes, and increase business value.
To further solidify their position as a trusted partner, Cognizant plans to establish an NVIDIA AI Center of Excellence. This center will allow them to innovate and leverage NVIDIA technologies, including the NVIDIA Metropolis, NVIDIA Omniverse, and NVIDIA AI Enterprise platforms, to benefit clients across industries globally.
Overall, the collaboration between Cognizant and NVIDIA in the field of drug discovery signifies a significant milestone. By combining their expertise and cutting-edge AI technology, they aim to accelerate the development of life-saving treatments and drive transformative changes in the industry, benefiting both clients and patients.
Sources:
– Cognizant: www.cognizant.com
– NVIDIA BioNeMo: www.nvidia.com